TAKEDA PHARMACEUTIC-SP ADR (TAK) Fundamental Analysis & Valuation

NYSE:TAK • US8740602052

17.77 USD
-0.35 (-1.93%)
At close: Mar 12, 2026
17.77 USD
0 (0%)
After Hours: 3/12/2026, 8:12:27 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TAK fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, TAK scores 5 out of 10 in our fundamental rating. TAK was compared to 193 industry peers in the Pharmaceuticals industry. While TAK has a great profitability rating, there are quite some concerns on its financial health. TAK is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

8

1. TAK Profitability Analysis

1.1 Basic Checks

  • In the past year TAK was profitable.
  • TAK had a positive operating cash flow in the past year.
  • TAK had positive earnings in each of the past 5 years.
  • TAK had a positive operating cash flow in each of the past 5 years.
TAK Yearly Net Income VS EBIT VS OCF VS FCFTAK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B 1T

1.2 Ratios

  • TAK has a Return On Assets of 0.73%. This is amongst the best in the industry. TAK outperforms 80.31% of its industry peers.
  • Looking at the Return On Equity, with a value of 1.48%, TAK belongs to the top of the industry, outperforming 82.38% of the companies in the same industry.
  • With a decent Return On Invested Capital value of 2.32%, TAK is doing good in the industry, outperforming 79.79% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for TAK is significantly below the industry average of 13.21%.
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROIC 2.32%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
TAK Yearly ROA, ROE, ROICTAK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2 4 6 8

1.3 Margins

  • TAK's Profit Margin of 2.53% is amongst the best of the industry. TAK outperforms 81.35% of its industry peers.
  • In the last couple of years the Profit Margin of TAK has grown nicely.
  • TAK has a better Operating Margin (10.76%) than 83.42% of its industry peers.
  • In the last couple of years the Operating Margin of TAK has grown nicely.
  • TAK's Gross Margin of 65.33% is fine compared to the rest of the industry. TAK outperforms 74.09% of its industry peers.
  • TAK's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
TAK Yearly Profit, Operating, Gross MarginsTAK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TAK Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so TAK is still creating some value.
  • The number of shares outstanding for TAK has been increased compared to 1 year ago.
  • Compared to 5 years ago, TAK has more shares outstanding
  • The debt/assets ratio for TAK has been reduced compared to a year ago.
TAK Yearly Shares OutstandingTAK Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
TAK Yearly Total Debt VS Total AssetsTAK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T

2.2 Solvency

  • TAK has an Altman-Z score of 1.23. This is a bad value and indicates that TAK is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of 1.23, TAK perfoms like the industry average, outperforming 58.03% of the companies in the same industry.
  • The Debt to FCF ratio of TAK is 6.48, which is on the high side as it means it would take TAK, 6.48 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 6.48, TAK belongs to the top of the industry, outperforming 82.38% of the companies in the same industry.
  • TAK has a Debt/Equity ratio of 0.56. This is a neutral value indicating TAK is somewhat dependend on debt financing.
  • TAK's Debt to Equity ratio of 0.56 is on the low side compared to the rest of the industry. TAK is outperformed by 63.21% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Altman-Z 1.23
ROIC/WACC1.41
WACC1.64%
TAK Yearly LT Debt VS Equity VS FCFTAK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2T 4T 6T

2.3 Liquidity

  • A Current Ratio of 1.19 indicates that TAK should not have too much problems paying its short term obligations.
  • TAK has a Current ratio of 1.19. This is in the lower half of the industry: TAK underperforms 77.20% of its industry peers.
  • A Quick Ratio of 0.65 indicates that TAK may have some problems paying its short term obligations.
  • TAK has a worse Quick ratio (0.65) than 85.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 0.65
TAK Yearly Current Assets VS Current LiabilitesTAK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500B 1T 1.5T 2T 2.5T

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. TAK Growth Analysis

3.1 Past

  • The earnings per share for TAK have decreased strongly by -45.17% in the last year.
  • The Earnings Per Share has been growing by 19.20% on average over the past years. This is quite good.
  • Looking at the last year, TAK shows a decrease in Revenue. The Revenue has decreased by -2.50% in the last year.
  • TAK shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.84% yearly.
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%

3.2 Future

  • Based on estimates for the next years, TAK will show a very strong growth in Earnings Per Share. The EPS will grow by 45.92% on average per year.
  • TAK is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.20% yearly.
EPS Next Y74.57%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
EPS Next 5YN/A
Revenue Next Year-1.2%
Revenue Next 2Y-0.15%
Revenue Next 3Y0.2%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TAK Yearly Revenue VS EstimatesTAK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
TAK Yearly EPS VS EstimatesTAK Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

6

4. TAK Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 77.26, the valuation of TAK can be described as expensive.
  • Based on the Price/Earnings ratio, TAK is valued a bit cheaper than the industry average as 77.20% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 25.71. TAK is valued rather expensively when compared to this.
  • The Price/Forward Earnings ratio is 30.15, which means the current valuation is very expensive for TAK.
  • 73.58% of the companies in the same industry are more expensive than TAK, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.82, TAK is valued a bit more expensive.
Industry RankSector Rank
PE 77.26
Fwd PE 30.15
TAK Price Earnings VS Forward Price EarningsTAK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TAK is valued cheaper than 87.56% of the companies in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of TAK indicates a rather cheap valuation: TAK is cheaper than 88.08% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.89
EV/EBITDA 10.64
TAK Per share dataTAK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • The excellent profitability rating of TAK may justify a higher PE ratio.
  • A more expensive valuation may be justified as TAK's earnings are expected to grow with 45.92% in the coming years.
PEG (NY)1.04
PEG (5Y)4.02
EPS Next 2Y65.4%
EPS Next 3Y45.92%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. TAK Dividend Analysis

5.1 Amount

  • TAK has a Yearly Dividend Yield of 3.55%.
  • Compared to an average industry Dividend Yield of 0.71, TAK pays a better dividend. On top of this TAK pays more dividend than 95.34% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, TAK pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.55%

5.2 History

  • The dividend of TAK has a limited annual growth rate of 1.18%.
  • TAK has been paying a dividend for at least 10 years, so it has a reliable track record.
  • TAK has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.18%
Div Incr Years2
Div Non Decr Years3
TAK Yearly Dividends per shareTAK Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 50 100 150

5.3 Sustainability

  • 277.04% of the earnings are spent on dividend by TAK. This is not a sustainable payout ratio.
  • TAK's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP277.04%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
TAK Yearly Income VS Free CF VS DividendTAK Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200B 400B 600B 800B
TAK Dividend Payout.TAK Dividend Payout, showing the Payout Ratio.TAK Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

TAK Fundamentals: All Metrics, Ratios and Statistics

TAKEDA PHARMACEUTIC-SP ADR

NYSE:TAK (3/12/2026, 8:12:27 PM)

After market: 17.77 0 (0%)

17.77

-0.35 (-1.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-30
Earnings (Next)05-13
Inst Owners47.91%
Inst Owner Change-0.91%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap56.14B
Revenue(TTM)4.46T
Net Income(TTM)112.93B
Analysts74.74
Price Target18.18 (2.31%)
Short Float %0.21%
Short Ratio2.19
Dividend
Industry RankSector Rank
Dividend Yield 3.55%
Yearly Dividend0.61
Dividend Growth(5Y)1.18%
DP277.04%
Div Incr Years2
Div Non Decr Years3
Ex-Date03-30
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.65%
Min EPS beat(2)-121.92%
Max EPS beat(2)90.61%
EPS beat(4)2
Avg EPS beat(4)-2.37%
Min EPS beat(4)-121.92%
Max EPS beat(4)90.61%
EPS beat(8)4
Avg EPS beat(8)-37%
EPS beat(12)6
Avg EPS beat(12)-26.29%
EPS beat(16)8
Avg EPS beat(16)-33.22%
Revenue beat(2)1
Avg Revenue beat(2)-2.91%
Min Revenue beat(2)-6.04%
Max Revenue beat(2)0.21%
Revenue beat(4)1
Avg Revenue beat(4)-3.67%
Min Revenue beat(4)-6.76%
Max Revenue beat(4)0.21%
Revenue beat(8)4
Avg Revenue beat(8)1.91%
Revenue beat(12)7
Avg Revenue beat(12)2.79%
Revenue beat(16)11
Avg Revenue beat(16)3.3%
PT rev (1m)3.21%
PT rev (3m)11.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-370.39%
EPS NY rev (1m)0.17%
EPS NY rev (3m)-11.2%
Revenue NQ rev (1m)1.66%
Revenue NQ rev (3m)3.1%
Revenue NY rev (1m)0.58%
Revenue NY rev (3m)0.33%
Valuation
Industry RankSector Rank
PE 77.26
Fwd PE 30.15
P/S 1.99
P/FCF 11.89
P/OCF 7.49
P/B 1.16
P/tB N/A
EV/EBITDA 10.64
EPS(TTM)0.23
EY1.29%
EPS(NY)0.59
Fwd EY3.32%
FCF(TTM)1.49
FCFY8.41%
OCF(TTM)2.37
OCFY13.36%
SpS8.91
BVpS15.26
TBVpS-3.25
PEG (NY)1.04
PEG (5Y)4.02
Graham Number8.89
Profitability
Industry RankSector Rank
ROA 0.73%
ROE 1.48%
ROCE 3.75%
ROIC 2.32%
ROICexc 2.47%
ROICexgc 10.72%
OM 10.76%
PM (TTM) 2.53%
GM 65.33%
FCFM 16.77%
ROA(3y)1.33%
ROA(5y)1.73%
ROE(3y)2.84%
ROE(5y)3.97%
ROIC(3y)2.65%
ROIC(5y)2.57%
ROICexc(3y)2.79%
ROICexc(5y)2.75%
ROICexgc(3y)14.77%
ROICexgc(5y)14.24%
ROCE(3y)4.3%
ROCE(5y)4.17%
ROICexgc growth 3Y-5.18%
ROICexgc growth 5Y8.79%
ROICexc growth 3Y-2.83%
ROICexc growth 5Y11.44%
OM growth 3Y-7.47%
OM growth 5Y6.82%
PM growth 3Y-28.5%
PM growth 5Y11.87%
GM growth 3Y-1.71%
GM growth 5Y-0.42%
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 6.48
Debt/EBITDA 3.48
Cap/Depr 58.95%
Cap/Sales 9.86%
Interest Coverage 4.11
Cash Conversion 96.87%
Profit Quality 663%
Current Ratio 1.19
Quick Ratio 0.65
Altman-Z 1.23
F-Score5
WACC1.64%
ROIC/WACC1.41
Cap/Depr(3y)69.03%
Cap/Depr(5y)56.25%
Cap/Sales(3y)11.53%
Cap/Sales(5y)9.44%
Profit Quality(3y)309.71%
Profit Quality(5y)308.48%
High Growth Momentum
Growth
EPS 1Y (TTM)-45.17%
EPS 3Y-22.57%
EPS 5Y19.2%
EPS Q2Q%341.77%
EPS Next Y74.57%
EPS Next 2Y65.4%
EPS Next 3Y45.92%
EPS Next 5YN/A
Revenue 1Y (TTM)-2.5%
Revenue growth 3Y8.68%
Revenue growth 5Y6.84%
Sales Q2Q%4.16%
Revenue Next Year-1.2%
Revenue Next 2Y-0.15%
Revenue Next 3Y0.2%
Revenue Next 5YN/A
EBIT growth 1Y0.22%
EBIT growth 3Y0.56%
EBIT growth 5Y14.13%
EBIT Next Year436.14%
EBIT Next 3Y77.24%
EBIT Next 5YN/A
FCF growth 1Y680.23%
FCF growth 3Y-8.86%
FCF growth 5Y9.4%
OCF growth 1Y62.56%
OCF growth 3Y-2%
OCF growth 5Y9.54%

TAKEDA PHARMACEUTIC-SP ADR / TAK FAQ

What is the fundamental rating for TAK stock?

ChartMill assigns a fundamental rating of 5 / 10 to TAK.


What is the valuation status for TAK stock?

ChartMill assigns a valuation rating of 6 / 10 to TAKEDA PHARMACEUTIC-SP ADR (TAK). This can be considered as Fairly Valued.


What is the profitability of TAK stock?

TAKEDA PHARMACEUTIC-SP ADR (TAK) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for TAK stock?

The Price/Earnings (PE) ratio for TAKEDA PHARMACEUTIC-SP ADR (TAK) is 77.26 and the Price/Book (PB) ratio is 1.16.


How financially healthy is TAKEDA PHARMACEUTIC-SP ADR?

The financial health rating of TAKEDA PHARMACEUTIC-SP ADR (TAK) is 3 / 10.